Bortezomib

Generic Name: Bortezomib

Brand Names: Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₅BN_₄O_₄

CAS Number: 179324-69-7

Unique Ingredient Identifier: 69G8BD63PP

Background: Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...

Indication: Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions: Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)

Associated Therapies: -

Clinical Trials

Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT00052507

Locations: 🇨🇦
Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦
Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada

and more 1 locations

PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2019-12-13

Lead Sponsor: University of Wisconsin, Madison

Registration Number: NCT00023855

Locations: 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States

Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Recurrent Ovarian Epithelial Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: bortezomib
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2019-07-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT00023712

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2011-04-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00028912

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Bortezomib in Treating Patients With Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 30

Registration Number: NCT00030875

Locations: 🇨🇦
Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada
🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada
🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada

and more 7 locations

Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Terminated

Conditions: Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: bortezomib

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00040768

Locations: 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Terminated

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2018-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00023881

Locations: 🇺🇸
MD Anderson Cancer Center at University of Texas, Houston, Texas, United States

PS-341 in Treating Patients With Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2009-12-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00017329

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Bortezomib in Treating Patients With Lymphoproliferative Disorders

Phase 2

Completed

Conditions: Recurrent Mantle Cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 1 Follicular Lymphoma

Interventions: Drug: bortezomib

First Posted Date: 2003-01-27

Last Posted Date: 2015-12-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 103

Registration Number: NCT00023764

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Bortezomib in Treating Children With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Drug: bortezomib
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00021216

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy